Entyvio (vedolizumab) blocks a protein on the surface of white blood cells that get into the gut and cause inflammation in ulcerative colitis and Crohn’s disease. By doing this, the amount of inflammation is reduced.1
Entyvio is used to treat the signs and symptoms in adults of:1
Ulcerative Colitis (UC) – Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.
Crohn’s Disease (CD) – Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.LEARN MORE
It is important that you read the Patient Information Leaflet that came with your medicine and keep a copy for future reference.
In addition, you should have been given a Patient Alert Card which contains important safety information and should be shown to any doctor involved in your treatment.Download the Entyvio Patient Information Leaflet
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com